PLX
Protalix BioTherapeutics
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NYSEAMERICAN: PLX
- PE Ratio
As of Jun 2, 2026, the Protalix BioTherapeutics stock's PE ratio is 10.47. This takes into account the latest EPS of $0.19 and stock price of $1.99.
PLX PE ratio history
The PE ratio of Protalix BioTherapeutics has averaged 20.13 over the last ten years. The current price-to-earnings ratio of 10.47 is 48% less than the historical average. Analyzing the last ten years, PLX's PE ratio reached its highest point in the Mar 2025 quarter at 51.2, when the price was $2.56 and the EPS was $0.05. The lowest point was recorded in the Sep 2016 quarter, when it reached 1.14 with a price of $5.7 and an EPS of $5.
Protalix BioTherapeutics PE ratio by year
Maximum annual increase: 216.93% in 2024
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | N/A | N/A | $1.8 | -$0.08 |
| 2024 | 47 | 216.93% | $1.88 | $0.04 |
| 2023 | 14.83 | N/A | $1.78 | $0.12 |
| 2022 | N/A | N/A | $1.37 | -$0.31 |
| 2021 | N/A | N/A | $0.83 | -$0.62 |
| 2020 | N/A | N/A | $3.63 | -$0.22 |
| 2019 | N/A | N/A | $3.28 | -$1.23 |
| 2018 | N/A | N/A | $3.11 | -$1.8 |
| 2017 | N/A | N/A | $6.61 | -$6.37 |
| 2016 | N/A | N/A | $4.45 | -$2.9 |
| 2015 | 1.67 | N/A | $10.2 | $6.1 |
| 2014 | N/A | N/A | $18.4 | -$3.2 |
| 2013 | N/A | N/A | $38.9 | -$3 |
| 2012 | N/A | N/A | $51.9 | -$1.3 |
| 2011 | N/A | N/A | $49.3 | -$4.3 |
Protalix BioTherapeutics PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 11.42 | N/A | $2.17 | $0.19 |
| Dec 2025 | N/A | N/A | $1.8 | -$0.08 |
| Sep 2025 | 31.71 | 71.41% | $2.22 | $0.07 |
| Jun 2025 | 18.5 | -63.87% | $1.48 | $0.08 |
| Mar 2025 | 51.2 | 8.94% | $2.56 | $0.05 |
| Dec 2024 | 47 | N/A | $1.88 | $0.04 |
| Sep 2024 | N/A | N/A | $1.02 | -$0.15 |
| Jun 2024 | N/A | N/A | $1.17 | -$0.22 |
| Mar 2024 | 12.6 | -15.04% | $1.26 | $0.1 |
| Dec 2023 | 14.83 | 25.04% | $1.78 | $0.12 |
| Sep 2023 | 11.86 | -40.7% | $1.66 | $0.14 |
| Jun 2023 | 20 | N/A | $2 | $0.1 |
| Mar 2023 | N/A | N/A | $2.1 | -$0.3 |
| Dec 2022 | N/A | N/A | $1.37 | -$0.31 |
| Sep 2022 | N/A | N/A | $1.04 | -$0.37 |
PLX Price vs fair value
PLX average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
The current PE ratio of PLX is under its 3, 5 and 10-year averages.
PE comparison
Protalix BioTherapeutics's price to earnings (P/E) of 10.47 is lower than the Healthcare sector and the industry average. Looking at the Healthcare sector average of 23.23, Protalix BioTherapeutics's price to earnings (P/E) is 55% lower.
PLX PE vs peers
When compared to its peer stocks PFE and TEVA, PLX's PE ratio is lower.
| Stock name | PE ratio | Market cap |
|---|---|---|
| PLX Protalix BioTherapeutics Inc | 10.32 | $157.92M |
| PFE Pfizer Inc | 19.34 | $144.42B |
| TEVA Teva Pharmaceutical Industries Ltd | 23.96 | $38.23B |
| NBIX Neurocrine Biosciences Inc | 24.61 | $16.6B |
Frequently asked questions
What is Protalix BioTherapeutics's PE ratio?
As of Jun 2, 2026, PLX stock has a price to earnings ratio of 10.47.
What is the 3-year average PE ratio for Protalix BioTherapeutics (PLX)?
Over the last 3 years, the average PE ratio for PLX stock is 24.35.
What is the 5-year average PE ratio for Protalix BioTherapeutics (PLX)?
Over the last 5 years, the average PE ratio for PLX stock is 24.35.
What is the highest PE ratio for PLX?
Over the last ten years, the quarterly PE ratio reached its highest level at 51.2 in the Mar 2025 quarter.
How does the current PE ratio for PLX compare to its historical average?
PLX's price to earnings ratio is currently 48% below its 10-year historical average.
How is PLX's PE ratio calculated (Protalix BioTherapeutics PE ratio formula)?
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (Jun 2, 2026), Protalix BioTherapeutics's share price is $1.99. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $0.19. Therefore, Protalix BioTherapeutics's price to earnings ratio for today is 10.47. PE RATIO(10.47) = STOCK PRICE($1.99) / TTM EPS($0.19)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.